I-5-Methylphenazinium methosulfate Cas: 299-11-6 99% Uhlaza olumnyama ukuya kumgubo omdaka
| Inombolo Yekhathalogu | XD90224 |
| Igama lemveliso | I-5-Methylphenazinium methosulfate |
| CAS | 299-11-6 |
| Ifomula yeemolekyuli | I-C14H14N2O4S |
| Ubunzima beMolekyuli | 306.337 |
| Iinkcukacha zokuGcina | -15 ukuya -20 °C |
| IKhowudi yoMrhumo eHarmonized | 29339980 |
Ukucaciswa kweMveliso
| Indawo yokunyibilika | 158-160 °C (dec.)(lit.) |
| Isivavanyi | 99% |
| Ifom | Iqinile |
| Imbonakalo | Buluhlaza omnyama ukuya kumgubo omdaka |
I-n-3 i-polyunsaturated fatty acids eicosapentaenoic acid (EPA) kunye ne-docosahexaenoic acid (DHA) zibonakaliswe ukwandisa umphumo wamachiza e-chemotherapeutic kwizifundo zeklinikhi kwizigulana ezinomhlaza kunye nokubangela ukufa kweseli ye-apoptotic kwi-vitro.Ukuza kuthi ga ngoku, i-EPA kunye ne-DHA azikaze ziphandwe kwi-myeloma eninzi (MM).Iiseli ze-myeloma zomntu (i-L363, i-OPM-1, i-OPM-2 kunye ne-U266) kunye neeseli zegazi eziqhelekileyo ze-peripheral ze-mononuclear zavezwa kwi-EPA kunye ne-DHA, kunye nemiphumo kwimisebenzi ye-mitochondrial kunye ne-apoptosis, i-activation ye-caspase-3, i-gene expression kunye ne-toxicity yeziyobisi yalinganiswa.Ukuvezwa kwi-EPA kunye ne-DHA kubangele i-apoptosis kunye nokwanda kovakalelo kwi-bortezomib kwiiseli ze-MM.Okubalulekileyo, azizange zichaphazele ukusebenza kweeseli eziqhelekileyo ze-peripheral mononuclear.I-Messenger ye-RNA yokubonisa i-arrays ibonise ukuba i-EPA kunye ne-DHA i-modulated genes ebandakanyekayo kwiindlela ezininzi zokubonisa iimpawu ezibandakanya i-nuclear factor (NF) κB, i-Notch, i-Hedgehog, uxinzelelo lwe-oxidative kunye ne-Wnt.I-EPA kunye ne-DHA ivimbele umsebenzi we-NFκB kwaye yenza i-apo ptosis ngokusebenzisa i-mitochondrial perturbation kunye ne-caspase-3 activation.Uphononongo lwethu lubonisa ukuba i-EPA kunye ne-DHA yenza imiphumo ekhethiweyo ye-cytotoxic kwi-MM kwaye yandise uvakalelo kwi-bortezomib kwaye ifuna ukuphononongwa okuqhubekayo kwi-application enokuthi ye-n-3 polyunsaturated fatty acids kunyango lwe-MM.
